Substance / Medication

Lesinurad

Overview

Active Ingredient
lesinurad
RxNorm CUI
1731031

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

17 trials linked to this intervention

17
Total Trials
4
Recruiting
2
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Effects of Food and Antacids on Pharmacokinetics and Pharmacodynamics of Lesinurad, a Selective Urate Reabsorption Inhibitor.
Shen Zancong, Lee Caroline A, Valdez Shakti et al. · Clin Pharmacol Drug Dev · 2019
PMID: 30748125RCT
Second-line treatment with lesinurad and allopurinol versus febuxostat for management of hyperuricemia: a cost-effectiveness analysis for Spanish patients.
Presa María, Pérez-Ruiz Fernando, Oyagüez Itziar · Clin Rheumatol · 2019
PMID: 31420811Observational
Evaluation of Pharmacokinetic Interactions Between Lesinurad, a New Selective Urate Reabsorption Inhibitor, and Commonly Used Drugs for Gout Treatment.
Shen Zancong, Tieu Kathy, Wilson David et al. · Clin Pharmacol Drug Dev · 2017
PMID: 28074640Observational
Pharmacokinetics, pharmacodynamics, and safety of lesinurad, a selective uric acid reabsorption inhibitor, in healthy adult males.
Shen Zancong, Rowlings Colin, Kerr Brad et al. · Drug Des Devel Ther · 2015
PMID: 26170627ObservationalFull text (PMC)
Different spectrophotometric methods for simultaneous determination of lesinurad and allopurinol in the new FDA approved pharmaceutical preparation; additional greenness evaluation.
Abdelazim Ahmed H, Abourehab Mohammed A S, Abd Elhalim Lobna M et al. · Spectrochim Acta A Mol Biomol Spectrosc · 2023
PMID: 36113304Other
Spectrophotometric quantitative analysis of lesinurad using extractive acid dye reaction based on greener selective computational approach.
Abdelazim Ahmed H, Ramzy Sherif · Spectrochim Acta A Mol Biomol Spectrosc · 2022
PMID: 35486984Other

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Lesinurad (substance)
SNOMED CT
715259003
UMLS CUI
C3886073
RxNorm CUI
1731031

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
17
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.